Switch theme
Sign up to access all valuation multiples
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
2021
27
Last FY Revenue $8.2M
Last FY EBITDA $2.4M
$334M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Anbio Biotechnology achieved revenue of $8.2M and an EBITDA of $2.4M.
Anbio Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anbio Biotechnology valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $8.2M | XXX | XXX | XXX |
| Gross Profit | XXX | $5.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 72% | XXX | XXX | XXX |
| EBITDA | XXX | $2.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 29% | XXX | XXX | XXX |
| EBIT | XXX | $2.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | 24% | XXX | XXX | XXX |
| Net Profit | XXX | $2.4M | XXX | XXX | XXX |
| Net Margin | XXX | 29% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Anbio Biotechnology's stock price is $8.
Anbio Biotechnology has current market cap of $345M, and EV of $334M.
See Anbio Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $334M | $345M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Anbio Biotechnology has market cap of $345M and EV of $334M.
Anbio Biotechnology's trades at 40.8x EV/Revenue multiple, and 140.6x EV/EBITDA.
Equity research analysts estimate Anbio Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anbio Biotechnology's P/E ratio is not available.
See valuation multiples for Anbio Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $345M | XXX | $345M | XXX | XXX | XXX |
| EV (current) | $334M | XXX | $334M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 40.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 140.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 167.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 145.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 160.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnbio Biotechnology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Anbio Biotechnology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anbio Biotechnology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Anbio Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anbio Biotechnology acquired XXX companies to date.
Last acquisition by Anbio Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Anbio Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Anbio Biotechnology founded? | Anbio Biotechnology was founded in 2021. |
| Where is Anbio Biotechnology headquartered? | Anbio Biotechnology is headquartered in United States of America. |
| How many employees does Anbio Biotechnology have? | As of today, Anbio Biotechnology has 27 employees. |
| Who is the CEO of Anbio Biotechnology? | Anbio Biotechnology's CEO is Mr. Michael Lau. |
| Is Anbio Biotechnology publicy listed? | Yes, Anbio Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Anbio Biotechnology? | Anbio Biotechnology trades under NNNN ticker. |
| When did Anbio Biotechnology go public? | Anbio Biotechnology went public in 2025. |
| Who are competitors of Anbio Biotechnology? | Similar companies to Anbio Biotechnology include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Anbio Biotechnology? | Anbio Biotechnology's current market cap is $345M |
| Is Anbio Biotechnology profitable? | Yes, Anbio Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
